Honasa Consumer to acquire 58% of Fluence Pharma at Rs 135 cr EV, enters Rs 16,000 cr supplements market
Mamaearth parent forms new subsidiary Honasa Health to enter nutraceuticals via Fluence Pharma buyout. Deal pegs 58% stake at Rs 135 cr EV, with remaining 42% over 5-7 years. Fluence guides Rs 40 cr FY26 revenue at 20%+ EBITDA margin, with reach across 3,000+ dermatologists.
Honasa Consumer, parent of Mamaearth, will acquire 58% of nutraceuticals firm Fluence Pharma at Rs 135 crore EV, with remaining 42% over 5-7 years, marking its entry into India's Rs 16,000 crore health supplements market via new subsidiary Honasa Health.